<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" bill-type="olc" dms-id="HC5CE22EEC8A144CFA39C95D8D3CD7F21" key="H" public-private="public">
	<metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>115 HR 6593 IH: Medication Automated Quotation System, or MEDAQ, Act of 2018</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2018-07-26</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
		<distribution-code display="yes">I</distribution-code>
		<congress display="yes">115th CONGRESS</congress><session display="yes">2d Session</session>
		<legis-num display="yes">H. R. 6593</legis-num>
		<current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber>
		<action display="yes">
			<action-date date="20180726">July 26, 2018</action-date>
			<action-desc><sponsor name-id="D000533">Mr. Duncan of Tennessee</sponsor> introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name></action-desc>
		</action>
		<legis-type>A BILL</legis-type>
		<official-title display="yes">To direct the Comptroller General of the United States to conduct a study on the feasibility of
			 establishing and maintaining an automated and searchable system that
			 tracks prescription drug prices in the United States, and for other
			 purposes.</official-title>
	</form>
	<legis-body id="H7A3DB3E3774F488C89643ACB1A87118C" style="OLC">
 <section id="HCB856995FF4B4D828FA34B5C12E759F0" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Medication Automated Quotation System, or MEDAQ, Act of 2018</short-title></quote>.</text> </section><section id="H48BCCBC767E34906BEFCED8ABAD6C7FC"><enum>2.</enum><header>Study on the feasibility of creating a system that tracks prescription drug costs</header> <subsection id="H85E73675DA5D4F09A3D288A5E9386BB6"><enum>(a)</enum><header>Study</header><text display-inline="yes-display-inline">The Comptroller General of the United States, in consultation with the Commissioner of Food and Drugs and the Administrator of CMS, shall conduct a study on the feasibility of establishing a medication automated quotation system.</text>
 </subsection><subsection id="HAA67B19B37A84ACCB5641BC20E453FA8"><enum>(b)</enum><header>Elements</header><text display-inline="yes-display-inline">The feasibility study required under subsection (a) shall include assessments of the following:</text> <paragraph id="HE78AB66ED20A4E2FA66CD8BC685B3A56"><enum>(1)</enum><text>The feasibility of—</text>
 <subparagraph id="HF821EE2D508D477197C2266E57949286"><enum>(A)</enum><text display-inline="yes-display-inline">collecting or compiling data on the acquisition price per unit that any purchaser (including but not limited to a distributor, a retailer, a third-party payor, or ultimate consumer) pays for a prescription drug and the effect PBMs and other involved entities have on such prices; and</text>
 </subparagraph><subparagraph id="HB569D50707BD485D996C2045F072AA0C"><enum>(B)</enum><text>aggregating such data in a manner that does not reveal personally identifiable information.</text> </subparagraph></paragraph><paragraph id="H40D523A0BD394AD3A23701AE573322E3"><enum>(2)</enum><text display-inline="yes-display-inline">The cost of procuring and maintaining a medication automated quotation system, or MEDAQ, based on the above data.</text>
 </paragraph><paragraph id="HBECA77B21E3641E78F95C02F8E7537BC"><enum>(3)</enum><text>The need for new or additional laws, regulations, or policies to collect the data necessary for a medication automated quotation system to track and generate prescription drug pricing data in the United States.</text>
 </paragraph><paragraph id="id03023A40D18748E2AFC08C1F1B2755B4"><enum>(4)</enum><text>The possibility of integrating or using the FDA's NDC system and CMS NADAC when creating the MEDAQ.</text> </paragraph><paragraph id="id6107E51405684CD3BFA5A13339655235"><enum>(5)</enum><text>Integration of CMS NADAC when creating the MEDAQ and, not withstanding any other provision of this Act, shall not consider pharmacy reporting, collecting, or compiling requirements beyond or in addition to the requirements of CMS NADAC.</text>
 </paragraph><paragraph id="H169E774B4BFD48E4B978190407D452A9"><enum>(6)</enum><text display-inline="yes-display-inline">Whether the system described under subsection (a) is likely to be effective in reducing overall prescription drug prices by increasing competition and transparency in the drug industry.</text>
 </paragraph></subsection><subsection id="H816F3CB5D5E5459BBED61ED6BBF80704"><enum>(c)</enum><header>Report</header><text display-inline="yes-display-inline">Not later than 270 days after the date of the enactment of this Act, the Comptroller General shall submit to Congress a report on the results of the study conducted under subsection (a).</text>
 </subsection><subsection id="H0A87CA08444F49E7AB3497D262A9C9D1"><enum>(d)</enum><header>Medication automated quotation system defined</header><text>The term <quote>medication automated quotation system</quote> or <quote>MEDAQ</quote> means an automated and searchable system that—</text> <paragraph id="H0F8DD5B3890649419824E150D1ED8364"><enum>(1)</enum><text>with respect to the United States (and with respect to each region thereof), tracks and generates data on the acquisition price per unit of any prescription drug that a purchaser pays for such unit of such drug;</text>
 </paragraph><paragraph id="H55F079C207D74FF081AA812DCB61EA90"><enum>(2)</enum><text>produces reports in real time on average prices per unit and other data; and</text> </paragraph><paragraph id="HE3118E142FA74648B392945BDF4B7200"><enum>(3)</enum><text display-inline="yes-display-inline">is accessible to purchasers, who have paid a user fee, with limitations to ensure appropriate privacy but also transparency in price negotiations.</text>
				</paragraph></subsection></section></legis-body>
</bill>


